RT Journal Article
SR Electronic
T1 Age-related clonal haematopoiesis is more prevalent in older adults with HIV: the ARCHIVE study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.19.20235069
DO 10.1101/2020.11.19.20235069
A1 Nila J. Dharan
A1 Paul Yeh
A1 Mark Bloch
A1 Miriam Yeung
A1 David Baker
A1 Jerick Guinto
A1 Norm Roth
A1 Sarah Ftouni
A1 Katherine Ognenovska
A1 Don Smith
A1 Jennifer F. Hoy
A1 Ian Woolley
A1 Catherine Pell
A1 David J. Templeton
A1 Neil Fraser
A1 Nectarios Rose
A1 Jolie Hutchinson
A1 Kathy Petoumenos
A1 Sarah-Jane Dawson
A1 Mark N. Polizzotto
A1 Mark A. Dawson
A1 for the ARCHIVE Study Group
YR 2020
UL http://medrxiv.org/content/early/2020/11/22/2020.11.19.20235069.abstract
AB People with HIV have higher rates of certain comorbidities, particularly cardiovascular disease and some malignancies, than people without HIV. As somatic mutations associated with age-related clonal haematopoiesis (CH) are linked to similar comorbidities in the general population, we hypothesized that CH may be more prevalent in people with HIV. To address this issue, we established a prospective cohort study recruiting 220 HIV-positive and 226 HIV-negative participants aged 55 years or older in Australia. Demographic characteristics, clinical data and peripheral blood were collected to assess for the presence of CH mutations and identify potential risk factors for and clinical sequelae of CH. Investigators testing for CH were blinded to participants’ HIV status. In total, 132 CH mutations were identified in 99 (22.2%) of 446 participants. CH was more prevalent in HIV-positive participants than HIV-negative participants (27.7% vs. 16.8%, p =0.006), overall and across all age groups. HIV infection was associated with an increased odds of having CH (adjusted odds ratio 2.10, 95% confidence interval 1.30-3.38, p=0.002). The most common genes mutated were DNMT3A (48.5%), TET2 (20.5%) and ASXL1 (11.4%). CH and HIV infection were independently associated with increases in blood parameters and biomarkers associated with inflammation. These data suggest a selective advantage for the emergence of CH in the context of chronic infection and inflammation related to HIV infection.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is an observational logitudinal cohort study. Trial registration number is being assigned. Unique protocol ID is 2020-11-ARCHIVE.Funding StatementM.A.D. has been a member of advisory boards for CTX CRC, Storm Therapeutics, Celgene and Cambridge Epigenetix. S.J.D has been a member of advisory boards for Astra Zeneca. The S.J.D. lab has received funding from CTx CRC and Genentech. The M.A.D. lab received research funding from CTx CRC. N.J.D. has received research support from Gilead Sciences Australia. D.E.S. has received research support and consultancy fees from: Gilead Sciences Australia, Janssen pharmaceuticals, Merck and Co, Sydney, Australia. J.H.'s institution has received reimbursement for her involvement in Advisory Boards for Gilead Sciences, Merch, Sharp & Dohme Australia and ViiV Healthcare. M.B. has received support for medical advisory boards, lecturing and attendance at scientific conferences from Gilead Sciences, ViiV Healthcare and Abbvie and his institution has received research support from Gilead Sciences, ViiV Healthcare, GSK, Abbvie, MSD, Amgen, and Eli Lilly.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by the St Vincent's Hospital Human Research Ethics Committee (HREC/17/SVH/182)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding authors upon reasonable request.